Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - Priority Announcement - Inflammatory Bowel Disease

University of Calgary

$45,000.00

Effects of Hydrogen sulfide on Pathogenic Disruptions of Microbiota Biofilms: Therapeutic Potential in Inflammatory Bowel Disease ?

EF 2012-13

Résumé
The treatment of Inflammatory Bowel Disease (IBD) represents a major medical challenge. Clinical observations implicate bacteria in IBD while antibiotics efficacy is controversial. For survival success, species of intestinal bacteria live in close relationships with other species in a glue-like substance to anchor in tissue. Those communities of bacteria sharing the same physical environment are named biofilms. Within those biofilms shelter, the population of bacteria is likely to enhanced resistance to antibiotics. This is probably why the use of antibiotics to treat IBD patients is inconsistent. The hydrogen sulfide is a gas known for his offensive rotten egg odor. It has useful role in some important functions of the gut. Recent preliminary studies have shown that hydrogen sulfide could modify the formation of a biofilm composed by a single species of human pathogenic bacteria. We propose that hydrogen sulfide could disrupt biofilms that contribute to IBD, thereby exerting protective effects. We will focus on human multispecies pathogenic biofilms collected from IBD patients of Foothills Medical Centre of Calgary, Alberta. First, we will evaluate if those biofilms could lead to a gut inflammation in recipient mice. Then, we will expose biofilms to hydrogen sulfide. In those experiments, the microbial composition and structure of biofilms will be performed using advanced techniques of microbial cultures, genetics and microscopy. Eventually, we will evaluate the therapeutic potential of using hydrogen sulfide to treat colitis in mice that received pathogenic biofilms. This proposal could provide further evidence that hydrogen sulfide can serve as the basis for an effective treatment of IBD.
Programme
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
270606
Name
Motta Jean-Paul
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario); Crohn's and Colitis Canada (Toronto, Ontario)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Effects of Hydrogen sulfide on Pathogenic Disruptions of Microbiota Biofilms: Therapeutic Potential in Inflammatory Bowel Disease ?
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Keyworddelim
Bacteria Biofilms; Drug Development; Hydrogen Sulfide; Inflammation; Inflammatory Bowel Disease; Innate Immunity; Mice Models Of Inflammatory Bowel Disease; Resolution Of Inflammation
Abstract
The treatment of Inflammatory Bowel Disease (IBD) represents a major medical challenge. Clinical observations implicate bacteria in IBD while antibiotics efficacy is controversial. For survival success, species of intestinal bacteria live in close relationships with other species in a glue-like substance to anchor in tissue. Those communities of bacteria sharing the same physical environment are named biofilms. Within those biofilms shelter, the population of bacteria is likely to enhanced resistance to antibiotics. This is probably why the use of antibiotics to treat IBD patients is inconsistent. The hydrogen sulfide is a gas known for his offensive rotten egg odor. It has useful role in some important functions of the gut. Recent preliminary studies have shown that hydrogen sulfide could modify the formation of a biofilm composed by a single species of human pathogenic bacteria. We propose that hydrogen sulfide could disrupt biofilms that contribute to IBD, thereby exerting protective effects. We will focus on human multispecies pathogenic biofilms collected from IBD patients of Foothills Medical Centre of Calgary, Alberta. First, we will evaluate if those biofilms could lead to a gut inflammation in recipient mice. Then, we will expose biofilms to hydrogen sulfide. In those experiments, the microbial composition and structure of biofilms will be performed using advanced techniques of microbial cultures, genetics and microscopy. Eventually, we will evaluate the therapeutic potential of using hydrogen sulfide to treat colitis in mice that received pathogenic biofilms. This proposal could provide further evidence that hydrogen sulfide can serve as the basis for an effective treatment of IBD.
Competitiondate
201210
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Motta, Jean-Paul
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $45,000~ $0~